Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway

Shu Wakino, Koichi Hayashi

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.

Original languageEnglish
Pages (from-to)693-699
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number4
Publication statusPublished - 2005 Apr

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway'. Together they form a unique fingerprint.

Cite this